Hepatocellular Carcinoma
Hepatocellular Carcinoma
Advertisement
Emily MenendezHepatocellular Carcinoma | April 18, 2024
Atezolizumab/bevacizumab and lenvatinib have both shown efficacy as first-line treatments for hepatocellular carcinoma.
Read More
Emily MenendezHepatocellular Carcinoma | March 27, 2024
The latest guideline update includes recommendations for first-, second-, and third-line therapy options.
Katy MarshallHepatocellular Carcinoma | March 7, 2024
Ablative therapy is an important treatment option for achieving a cancer-free state as HCC rates continue to rise.
Katy MarshallHepatocellular Carcinoma | February 26, 2024
Researchers found that patients with diabetes and higher alpha-fetoprotein had decreased OS rates.
Emily MenendezASCO GI 2024 | February 7, 2024
In patients with HCC, a high CD8 and low TIM3 expression is linked to better OS than PD-1/PD-L1.
Elizabeth Conner, MDASCO GI 2024 | January 25, 2024
Dr. Elizabeth Conner offers insight on how DCP can be utilized as a biomarker for treatment response in patients with HCC.
Emily MenendezASCO GI 2024 | January 23, 2024
A new report detailed the results of the LEAP-002 study following 12 months of additional follow-up.
Zachary BessetteASCO GI 2024 | January 23, 2024
An analysis of demographic, clinical characteristics, and treatment patterns for HCC for defining early-stage disease.
Julien Calderaro, MD, PhDHepatocellular Carcinoma | January 23, 2024
Dr. Julien Calderaro explains the potential of AI to serve as a biomarker of sensitivity to atezolizumab plus bevacizumab.
Josep M. Llovet, MDHepatocellular Carcinoma | January 23, 2024
Drs. Llovet and Finn consider how LEAP-002 adds to the debate around IO/VEGF, IO/IO, and IO/TKI for aHCC.
Josep M. Llovet, MDHepatocellular Carcinoma | January 23, 2024
Drs. Llovet and Finn provide a high-level understanding of LEAP-002, looking at lenvatinib/pembrolizumab for 1L aHCC.
Emily MenendezHepatocellular Carcinoma | December 18, 2023
The CRAFITY score is based on C-reactive protein and serum AFP in immunotherapy to predict prognosis in patients with HCC..
Emily MenendezHepatocellular Carcinoma | December 18, 2023
The combination can serve as a potential first-line treatment for patients aged 80 years or older.
Amit Mahipal, MDHepatocellular Carcinoma | January 23, 2024
Drs. Mahipal and Finn share the safety and prognostic considerations for patients with aHCC receiving lenvatinib after IO.
Amit Mahipal, MDHepatocellular Carcinoma | January 23, 2024
Drs. Mahipal and Finn discuss real-world outcomes for hepatocellular carcinoma patients receiving lenvatinib following IO.
Zachary BessetteHepatocellular Carcinoma | December 4, 2023
According to a recent study, DAAs remain underutilized in patients with HCV-related HCC, despite improved survival outcomes.
Fatema Tashrifwala, MDHepatocellular Carcinoma | January 23, 2024
Dr. Fatema Tashrifwala explains new research highlighting the effectiveness of TACE plus camrelizumab.
Katy MarshallHepatocellular Carcinoma | November 21, 2023
Investigators determined that progression-free survival for patients who received TACE plus camrelizumab was 6.2 months.
Katy MarshallHepatocellular Carcinoma | November 21, 2023
Investigators also researched the possibility that AI could predict progression-free survival.
Katy MarshallHepatocellular Carcinoma | November 10, 2023
Researchers analyzed the effects of the 2015 MELD except policy change on liver transplants for patients with HCC.
Advertisement
Advertisement
Advertisement
Latest News

April 24, 2024